AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
Lausanne, Switzerland, January 3, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on Neurodegenerative Diseases, today announced that it has appointed Dr. Marie Kosco-Vilbois, as Chief Scientific Officer, effective January 3, 2019. Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: "I am delighted to welcome Dr. Marie Kosco-Vilbois as our Chief Scientific Officer. The Company will benefit greatly from her extensive experience in Immunology and Drug Development, which will enhance growth of the Company's robust pipeline in Neurodegenerative Diseases." In this position, Dr. Kosco-Vilbois will report directly to CEO Andrea Pfeifer. To facilitate her rapid integration into the Company she will be supported by Dr. David Lowe who has led AC Immune's Research ad interim and has held senior R&D roles in the Company since 2014. About Dr. Marie Kosco-Vilbois Dr. Kosco-Vilbois, a US citizen, has extensive
[Read more]
| Impact snapshot | Event time: | ACIU | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ACIU alerts
ACIU alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune acquires Parkinson’s disease vaccine candidate, launches private placement [Seeking Alpha]Seeking Alpha
- AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseasesGlobeNewswire
- AC Immune lures BioNTech investors, buys Parkinson's vaccine candidate [Reuters]Reuters
- AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbHGlobeNewswire
- AC Immune SA (<a href="https://www.marketbeat.com/stocks/NASDAQ/ACIU/price-target/">NASDAQ: ACIU</a>) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
- More
ACIU
SEC Filings
- 7/27/21 - Form 6-K
- 6/25/21 - Form 6-K
- 5/21/21 - Form 6-K
- ACIU's page on the SEC website
- More